menu
    • menu
    [{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"TP-03","moa":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Topical","sponsorNew":"Tarsus Pharmaceuticals \/ Vivo Capital","highestDevelopmentStatusID":"9","companyTruncated":"Tarsus Pharmaceuticals \/ Vivo Capital"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TP-03","moa":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"TP-03","moa":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA A receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA A receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA A receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"LianBio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Tarsus Pharmaceuticals \/ Tarsus Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Tarsus Pharmaceuticals \/ Tarsus Pharmaceuticals"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Lotilaner","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Lotilaner","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Lotilaner","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Tarsus Pharmaceuticals

    Menu

    Tarsus Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Goldman Sachs & Co. LLC

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Tarsus Announces Pricing of $100.0 Million Public Offering

                            Details : Proceeds will be used for the U.S. commercialization of Xdemy (lotilaner), designed to target and kill Demodex mites causing Demodex blepharitis.

                            Brand Name : Xdemvy

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 29, 2024

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Goldman Sachs & Co. LLC

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tarsus Reports Positive Results from Phase 2a Trial of TP-05 for Lyme Disease Prevention

                            Details : TP-05 (lotilaner) is an oral, well-characterized anti-parasitic agent that selectively inhibits parasite-specific GABA-Cl channels. It is being evaluated for the prevention of Lyme Disease.

                            Brand Name : TP-05

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 22, 2024

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treat...

                            Details : TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel small molecule, approved for Demodex blepharitis under the brand name Xdemvy. Now it is being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients w...

                            Brand Name : TP-03

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 11, 2023

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Goldman Sachs & Co. LLC

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

                            Details : The company intends to use the net proceeds to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease...

                            Brand Name : Xdemvy

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 01, 2023

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Goldman Sachs & Co. LLC

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Goldman Sachs & Co. LLC

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

                            Details : The company intends to fund the commercial launch of Xdemvy (lotilaner) for the treatment of Demodex blepharitis in the United States and to develop its product pipeline including TP-03 for the treatment of Meibomian Gland Disease, or MGD, TP-04 and TP-0...

                            Brand Name : Xdemvy

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 31, 2023

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Goldman Sachs & Co. LLC

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis

                            Details : Xdemvy (lotilaner ophthalmic solution), a novel prescription eye drop, is recently approved by FDA and is designed to treat demodex blepharitis by targeting and eradicating the root cause of the disease, demodex mite infestation.

                            Brand Name : Xdemvy

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 25, 2023

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : LianBio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blephari...

                            Details : TP-03 (lotilaner) is a novel investigational therapeutic designed to resolve the signs and symptoms of Demodex blepharitis by targeting and eradicating the root cause of the demodex mite infestation.

                            Brand Name : TP-03

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 08, 2023

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : LianBio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Ki...

                            Details : TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills ticks that transmit Lyme disease by selectively inhibiting parasite-specific GABA-CI channels.

                            Brand Name : TP-05

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 15, 2022

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Ann...

                            Details : TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.

                            Brand Name : TP-03

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 25, 2022

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Tarsus Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evalu...

                            Details : TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation.

                            Brand Name : TP-03

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 27, 2022

                            Lead Product(s) : Lotilaner

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth